pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Estradiol Noven
drug
save

estradiol ER

Marketedupdated 6mo ago
by Noven Pharmaceuticals Inc
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 12 approved and 41 investigational indications.

all catalysts(22)

approval · 22
Apr 26, 1996
approval
$PFE28.86-0.10%
31y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Apr 18, 1997
approval
$PFE28.86-0.10%
30y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Dec 29, 1998
approval
28y ago
ESTRADIOL — FDA approval
estradiol ER
→
Sep 24, 1999
approval
27y ago
ESTRADIOL — FDA approval
estradiol ER
→
Nov 1, 1999
approval
27y ago
ESTRADIOL — FDA approval
estradiol ER
→
Nov 1, 1999
approval
27y ago
ESTRADIOL — FDA approval
estradiol ER
→
Jan 5, 2000
approval
$PFE28.86-0.10%
27y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
May 16, 2000
approval
$PFE28.86-0.10%
27y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Jul 24, 2001
approval
$PFE28.86-0.10%
25y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Aug 25, 2008
approval
$PFE28.86-0.10%
18y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
May 16, 2014
approval
$PFE28.86-0.10%
13y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Aug 12, 2014
approval
$PFE28.86-0.10%
12y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Sep 29, 2015
approval
$PFE28.86-0.10%
11y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Sep 29, 2015
approval
$PFE28.86-0.10%
11y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Nov 1, 2017
approval
$PFE28.86-0.10%
9y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Jan 4, 2019
approval
8y ago
ESTRADIOL — FDA approval
estradiol ER
→
Jul 27, 2022
approval
$PFE28.86-0.10%
4y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Feb 15, 2024
approval
$PFE28.86-0.10%
3y ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Feb 16, 2024
approval
3y ago
ESTRADIOL — FDA approval
estradiol ER
→
Dec 8, 2025
approval
11mo ago
ESTRADIOL — FDA approval
estradiol ER
→
Jan 22, 2026
approval
10mo ago
ESTRADIOL — FDA approval
estradiol ER
→
Feb 12, 2026
approval
$PFE28.86-0.10%
9mo ago
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
view all 22 catalysts →

Trials studying estradiol ER

  • phase1A Study to Assess the Bioavailability and Adhesion of Estradiol/Levonorgestrel TDS in Healthy Post-Menopausal Female Participantscompletedn=68
  • phase3Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)not yet recruitingn=1,600
  • phase1A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjectsrecruitingn=250
  • phase1A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignanciesrecruitingn=24
  • phase1A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participantscompletedn=15
  • phase1Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)recruitingn=24
  • phase1A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesityrecruitingn=50
  • phase3The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trialrecruitingn=110

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 10, 2028
~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (55)

  • Feb 2, 2034method-of-use (U-2317)US 11266661
  • Feb 2, 2034method-of-use (U-2317)US 11266661
  • Nov 21, 2032method-of-use (U-2317)US 10258630
  • Nov 21, 2032method-of-use (U-2317)US 10258630
  • Nov 21, 2032method-of-use (U-2614)US 10398708
  • Nov 21, 2032method-of-use (U-2614)US 10398708
  • Nov 21, 2032method-of-use (U-2316)US 10471072
  • Nov 21, 2032method-of-use (U-2316)US 10471072
  • Nov 21, 2032formulationUS 10537581
  • Nov 21, 2032formulationUS 10537581
  • Nov 21, 2032method-of-use (U-2316)US 10568891
  • Nov 21, 2032method-of-use (U-2317)US 10568891
  • Nov 21, 2032method-of-use (U-2317)US 10668082
  • Nov 21, 2032method-of-use (U-2316)US 10668082
  • Nov 21, 2032formulationUS 10806697
  • Nov 21, 2032formulationUS 10806697
  • Nov 21, 2032method-of-use (U-2316)US 10835487
  • Nov 21, 2032method-of-use (U-2317)US 10835487
  • Nov 21, 2032method-of-use (U-2317)US 10888516
  • Nov 21, 2032method-of-use (U-2317)US 10888516
  • Nov 21, 2032formulationUS 11065197
  • Nov 21, 2032formulationUS 11065197
  • Nov 21, 2032formulationUS 11116717
  • Nov 21, 2032formulationUS 11116717
  • Nov 21, 2032formulationUS 11123283
  • Nov 21, 2032formulationUS 11123283
  • Nov 21, 2032method-of-use (U-2317)US 11241445
  • Nov 21, 2032method-of-use (U-2316)US 11241445
  • Nov 21, 2032method-of-use (U-2316)US 11246875
  • Nov 21, 2032method-of-use (U-2317)US 11246875
  • Nov 21, 2032formulationUS 11304959
  • Nov 21, 2032formulationUS 11304959
  • Nov 21, 2032method-of-use (U-2317)US 11351182
  • Nov 21, 2032method-of-use (U-2317)US 11351182
  • Nov 21, 2032method-of-use (U-2317)US 11497709
  • Nov 21, 2032formulationUS 9180091
  • Nov 21, 2032formulationUS 9180091
  • Nov 21, 2032formulationUS 9289382
  • Nov 21, 2032formulationUS 9289382
  • Jul 4, 2030compositionUS 82319063.6y
  • Jul 4, 2030compositionUS 82319063.6y
  • Jul 4, 2030compositionUS 82319063.6y
  • Jul 4, 2030compositionUS 82319063.6y
  • Jul 4, 2030compositionUS 82319063.6y
  • Jul 10, 2028compositionUS 97243101.6y
  • Jul 10, 2028method-of-use (U-2086)US 97309001.6y
  • Jul 10, 2028method-of-use (U-2086)US 97309001.6y
  • Jul 10, 2028method-of-use (U-2086)US 97309001.6y
  • Jul 10, 2028formulationUS 97309001.6y
  • Jul 10, 2028method-of-use (U-2086)US 97309001.6y
  • Jul 10, 2028formulationUS 98334191.6y
  • Jul 10, 2028formulationUS 98334191.6y
  • Jul 10, 2028formulationUS 98334191.6y
  • Jul 10, 2028formulationUS 98334191.6y
  • Jul 10, 2028formulationUS 98334191.6y

News(3)

  • This Week at FDA: New ConOps for drug inspections, AI policy proposal, and more
    Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This wee…
    raps · 18d ago
  • FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women
    Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy pa…
    fda_press · 27d ago
  • Breast cancer can behave differently in older women. This physician is making more tailored treatments a reality
    There’s increasing evidence that older women with breast cancer could benefit from more tailored treatments. STAT Wunderkind Neil Carleton is working to make that a reality.
    stat · 1mo ago
brand
Estradiol Noven
generic
estradiol
MOA
Estrogen receptor alpha agonist
indication
Vasomotor Symptoms of Menopause (Hot Flashes)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?